← All organizations
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2015First marketed drug
Jan 9, 2020First NDA
Jan 9, 2020Last known activity
May 28, 2025
Acquired by Sanofi-Aventis on Jun 2, 2025
Timeline
2010s
- Jun 1, 2011
Blueprint Medicines Corporation— Founded
2020s
- Jan 9, 2020
avapritinib— NDA Organization
- Jan 9, 2020
avapritinib— NDA Secondary Org
- Sep 4, 2020
pralsetinib— Marketing Organization
- Dec 1, 2021
Lengo Therapeutics— Acquired
- Jun 2, 2025
Sanofi-Aventis— Acquired By
Drugs by trial phase (24 distinct, 27 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma, Papillary
- Bronchial Diseases
- Bronchial Neoplasms
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Colonic Diseases
- Colonic Neoplasms
- Colorectal Neoplasms
- Digestive System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Endocrine System Diseases
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Head and Neck Neoplasms
- Hematologic Neoplasms
- Intestinal Diseases
- Intestinal Neoplasms
- Leukemia, Mast-Cell
- Lung Diseases
- Lung Neoplasms
- Mastocytosis
- Mastocytosis, Systemic
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Glandular and Epithelial
- Neoplasms, Nerve Tissue
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neuroendocrine Tumors
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Thyroid Cancer, Papillary
- Thyroid Diseases
- Thyroid Neoplasms
Marketed drugs (2)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (27)
- NCT04204928Lead sponsorN/A—
- NCT03862885Lead sponsorN/A—
- NCT04714086Lead sponsorN/A—
- NCT06931405Lead sponsorPhase 2May 28, 2025
- NCT06922448Lead sponsorPhase 2Apr 14, 2025
- NCT06748001Lead sponsorPhase 4Nov 28, 2024
- NCT06948032Lead sponsorPhase 1Aug 7, 2024
- NCT06327685CollaboratorPhase 1Mar 13, 2024
- NCT05609942Lead sponsorPhase 1/Phase 2Dec 1, 2022
- NCT05252416Lead sponsorPhase 1/Phase 2Apr 7, 2022
- NCT05241873Lead sponsorPhase 1/Phase 2Mar 4, 2022
- NCT05153408Lead sponsorPhase 1/Phase 2Dec 10, 2021
- NCT04773782Lead sponsorPhase 1/Phase 2Nov 30, 2021
- NCT04910685Lead sponsorPhase 2/Phase 3Oct 6, 2021
- NCT04908176Lead sponsorPhase 1Jul 31, 2021
Details
- Founded
- Cambridge, MA, US Jun 1, 2011
- First NDA
- Jan 9, 2020
- Last known activity
- May 28, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy